A multicentre randomised double-blind parallel group placebo controlled study assessing the efficacy and safety of inhaled salmeterol/fluticasone 50/500mcg twice daily, inhaled fluticasone 500mcg twice daily and placebo all administered via MDI in the treatment of patients with COPD

Trial Profile

A multicentre randomised double-blind parallel group placebo controlled study assessing the efficacy and safety of inhaled salmeterol/fluticasone 50/500mcg twice daily, inhaled fluticasone 500mcg twice daily and placebo all administered via MDI in the treatment of patients with COPD

Completed
Phase of Trial: Phase III

Latest Information Update: 22 May 2015

At a glance

  • Drugs Salmeterol/fluticasone propionate (Primary) ; Fluticasone propionate
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 22 May 2015 Post-hoc analysis results from this and two other trials (SCO40036 and SFCB3024) presented at the American Thoracic Society (ATS) meeting 2015, according to a GlaxoSmithKline media release.
    • 22 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top